Laura Silvius, Managing Editor

The FDA approves Flow's at-home depression treatment headset, offering a new approach to managing mental health with transcranial stimulation technology.

Pharmacists debate the effectiveness and ethics of GLP-1 agonists for pediatric obesity, highlighting the need for balanced treatment approaches.

Pharmacists explore AI's transformative potential, evaluating its applications and ensuring ethical integration to enhance patient care and pharmacy operations.

Economic factors are driving sterile injectable drug shortages, but collaborative strategies can enhance health care industry resiliency.

Pharmacists can enhance patient care through integrated treatment strategies.

Rural hospitals face a crisis, but pharmacists can expand services to alleviate the uninsured patient burden and enhance community health.

Pharmacist-led refill authorizations enhance outpatient care, reduce physician burnout, and streamline pharmacy management in health systems, improving patient satisfaction.

Emerging pharmacy trends will be highlighted at the American Society of Health-System Pharmacists (ASHP) Midyear 2025, including AI innovations, GLP-1 therapies, and evolving geriatric and neonatal care.

Sibeprenlimab offers a groundbreaking treatment for immunoglobulin A nephropathy, targeting APRIL to reduce kidney damage and improve patient outcomes.

The FDA approves a reformulated ranitidine, addressing past safety concerns while treating GERD and peptic ulcers.

SGLT2 inhibitors significantly reduce atrial fibrillation risk and improve heart failure outcomes, outperforming GLP-1 agonists in cardiovascular benefits.

Researchers explore HER3-targeted therapy with patritumab deruxtecan to enhance outcomes in early-stage triple-negative breast cancer, reducing chemotherapy side effects.

A phase 2 trial suggests a stepwise regimen using liposomal irinotecan followed by oxaliplatin may improve progression-free survival over standard treatment.

If approved, SYD-101 would have been the first FDA-approved treatment for pediatric myopia, offering hope to millions of affected children in the US.

CVS expands its footprint by acquiring 626 Rite Aid and Bartell locations, enhancing pharmacy access amid industry challenges.

The pharmaceutical giant will reportedly lower its drug prices to align with most-favored-nation status.

Remibrutinib gains FDA approval as the first oral treatment for chronic hives, offering hope for patients unresponsive to standard therapies.

New research reveals how BCMA mutations in multiple myeloma affect the efficacy of immunotherapy drugs, guiding treatment decisions for patients.

Iberdomide enhances chimeric antigen receptor (CAR) T-cell therapy effectiveness in multiple myeloma, boosting immune response and cell functionality.

Teclistamab shows promising results in newly diagnosed multiple myeloma, enhancing tolerability and achieving high rates of minimal residual disease negativity.

Promising phase 2 results for taletrectinib in ROS1+ lung cancer show significant tumor shrinkage and manageable adverse effects.

A recent phase 3 study reveals osimertinib combined with chemotherapy offers unprecedented survival rates for patients with advanced EGFR-mutated lung cancer.

Experts forecast a potential resurgence of measles and other vaccine-preventable diseases in the U.S. due to declining vaccination rates.